Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions View by Topic View by Date Must Reads In Leukemia, Myelodysplasia, Transplantation Leukemia, Myelodysplasia, Transplantation for November/December 2020 Well tolerated with promising responses in ALL/LL: Venetoclax plus navitoclax plus chemotherapy, Highly effective in Ph-negative B-cell ALL: Hyper-CVAD with sequential blinatumomab, Immune checkpoint inhibitors don’t increase COVID-19 incidence or mortality, studies suggest, New cancer drugs may have saved more than 1.2 million Americans, Ibrutinib associated with decreased circulating malignant cells and restored T-cell function in CLL patients, More must reads Leukemia, Myelodysplasia, Transplantation for September/October 2020 Final ASCEND study data: Acalabrutinib beat standard of care for r/r CLL, Study: Complications from childhood ALL and its treatment are common, but can be managed, Meta-analysis: Acalabrutinib showed better PFS and OS than other frontline CLL therapies, Orthopedic problems in children can be the first indication of acute lymphoblastic leukemia, Two new protein biomarkers may serve as prognostic indicators for outcomes in CLL, More must readsLeukemia, Myelodysplasia, Transplantation for July/August 2020 VTE, sepsis risk increased among COVID-19 patients with cancer, Aspirin may accelerate cancer progression in older adults, Antihistamines synergistically induce CLL cell death with TK inhibitors, Polygenic risk score may predict VTE in adolescents, but not adults, with ALL, BALL score predicts benefit from ibrutinib therapy in relapsed/refractory CLL patients, More must readsLeukemia, Myelodysplasia, Transplantation for May/June 2020 Combo drug improves survival in older patients with high-risk/secondary AML, Venetoclax plus LDAC tops LDAC alone in AML, Azacitidine plus enasidenib improves response, but not survival, in mIDH2 AML, HSCT may be best option for therapy-related ALL, Ibrutinib-venetoclax produces high MRD-negative rates in CLL/SLL, More must readsLeukemia, Myelodysplasia, Transplantation for March/April 2020 Metastatic cancer linked to worse outcomes of COVID-19, Five prognostic indexes come up short for planning early CLL treatment, CLAM trial regimen shown safe, effective for r/r AML, Cancer prevalence among COVID-19 patients may be higher than previously reported, One-third of high-risk CLL patients received treatment counter to recommendations, More must readsPages1 2 3 4 5 last »
